Plus Therapeutics, Inc. (NASDAQ:PSTV) Sees Large Increase in Short Interest

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the recipient of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 52,700 shares, an increase of 51.0% from the August 31st total of 34,900 shares. Approximately 0.9% of the company’s shares are sold short. Based on an average daily trading volume, of 54,300 shares, the short-interest ratio is currently 1.0 days.

Analysts Set New Price Targets

PSTV has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Plus Therapeutics in a report on Friday, August 16th. Ascendiant Capital Markets lowered their price objective on Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd.

Institutional Investors Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC bought a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned approximately 9.98% of Plus Therapeutics as of its most recent SEC filing. 3.28% of the stock is currently owned by hedge funds and other institutional investors.

Plus Therapeutics Price Performance

Plus Therapeutics stock traded up $0.31 during trading hours on Friday, reaching $1.85. The stock had a trading volume of 370,333 shares, compared to its average volume of 56,610. The company has a fifty day simple moving average of $1.55 and a 200-day simple moving average of $1.78. Plus Therapeutics has a 52 week low of $0.97 and a 52 week high of $2.78. The stock has a market cap of $10.55 million, a PE ratio of -0.61 and a beta of 0.65.

Plus Therapeutics (NASDAQ:PSTV) last posted its earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share (EPS) for the quarter. Plus Therapeutics had a negative return on equity of 805.57% and a negative net margin of 240.15%. The business had revenue of $1.28 million during the quarter. Research analysts predict that Plus Therapeutics will post -2.22 earnings per share for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.